Evolution of Acute Pulmonary Embolism Management: Review Article

Curr Probl Cardiol. 2021 Mar;46(3):100551. doi: 10.1016/j.cpcardiol.2020.100551. Epub 2020 Feb 14.

Abstract

Acute pulmonary emboli are a major cause of morbidity and mortality and require prompt evaluation, diagnosis, and treatment. To date, anticoagulation using low molecular weight heparin or non-Vitamin K oral anticoagulants has been the mainstay of treatment in the subset of patients in whom pulmonary embolism does not compromise hemodynamics. On the other hand however, patients with massive pulmonary embolism and shock, thrombolytic therapy is necessary. This raises the question whether ultrasound-assisted catheter directed thrombolytic delivery might be superior to systemic administration. This review article aims to consolidate recent literature to help achieve a better understanding toward the utility of catheter directed therapy.

Publication types

  • Review

MeSH terms

  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Pulmonary Embolism* / diagnosis
  • Pulmonary Embolism* / drug therapy
  • Thrombolytic Therapy
  • Treatment Outcome

Substances

  • Anticoagulants
  • Fibrinolytic Agents